Illustrative image – not actual.Aarti Pharmalabs has announced plans to maintain capital expenditure at approximately Rs 400 crore in FY2027, in line with its FY2026 investment levels.
The planned spending will be directed towards the ongoing Xanthine expansion project, debottlenecking initiatives at its Tarapur Unit-4 facility, and the proposed development of a new production block at its Atali manufacturing site.
The investments are aimed at enhancing production capacity and supporting the company's long-term growth strategy.
